CA3121241A1 - Pegylated growth hormone antagonists - Google Patents

Pegylated growth hormone antagonists Download PDF

Info

Publication number
CA3121241A1
CA3121241A1 CA3121241A CA3121241A CA3121241A1 CA 3121241 A1 CA3121241 A1 CA 3121241A1 CA 3121241 A CA3121241 A CA 3121241A CA 3121241 A CA3121241 A CA 3121241A CA 3121241 A1 CA3121241 A1 CA 3121241A1
Authority
CA
Canada
Prior art keywords
growth hormone
human growth
polyethylene glycol
cysteine
hormone receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3121241A
Other languages
English (en)
French (fr)
Inventor
Richard S. Brody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Technologies Laboratories LLC
Original Assignee
Molecular Technologies Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/216,230 external-priority patent/US10874717B2/en
Application filed by Molecular Technologies Laboratories LLC filed Critical Molecular Technologies Laboratories LLC
Publication of CA3121241A1 publication Critical patent/CA3121241A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3121241A 2018-12-11 2019-12-10 Pegylated growth hormone antagonists Pending CA3121241A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/216,230 US10874717B2 (en) 2015-07-07 2018-12-11 Pegylated growth hormone antagonists
US16/216,230 2018-12-11
PCT/US2019/065385 WO2020123450A1 (en) 2018-12-11 2019-12-10 Pegylated growth hormone antagonists

Publications (1)

Publication Number Publication Date
CA3121241A1 true CA3121241A1 (en) 2020-06-18

Family

ID=71076634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121241A Pending CA3121241A1 (en) 2018-12-11 2019-12-10 Pegylated growth hormone antagonists

Country Status (4)

Country Link
EP (1) EP3893919A4 (https=)
JP (2) JP2022511951A (https=)
CA (1) CA3121241A1 (https=)
WO (1) WO2020123450A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250101076A1 (en) * 2023-09-22 2025-03-27 Molecular Technologies Laboratories Llc Growth hormone receptor antagonists exhibiting increased receptor binding properties and increased serum half-life

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
BRPI0519430A2 (pt) * 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
US20170007711A1 (en) * 2015-07-07 2017-01-12 Richard S. Brody Pegylated growth hormone antagonists
US10874717B2 (en) 2015-07-07 2020-12-29 Burr Oak Therapeutics LLC Pegylated growth hormone antagonists
WO2019211842A1 (en) 2018-04-30 2019-11-07 Opko Biologics Ltd. Long-acting human growth hormone-antagonists and methods of producing the same

Also Published As

Publication number Publication date
JP2022511951A (ja) 2022-02-01
WO2020123450A1 (en) 2020-06-18
EP3893919A4 (en) 2022-11-30
JP2025026898A (ja) 2025-02-26
EP3893919A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
US10874717B2 (en) Pegylated growth hormone antagonists
US20170007711A1 (en) Pegylated growth hormone antagonists
JP6023703B2 (ja) 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
EP3642340B1 (en) Modified l-asparaginase
CN102234310B (zh) 一种聚乙二醇修饰蛋白的分离纯化方法
US10174302B1 (en) Modified L-asparaginase
CN107207623B (zh) Fc融合高亲和力IgE受体α链
US20160024179A1 (en) Modified fc fusion proteins
AU2017357327B2 (en) Pegylated endostatin analogue and application thereof
CA2710841A1 (en) Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof
CN111153965A (zh) 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
EP3154563B1 (en) New polypeptide
JP2025026898A (ja) Ｐｅｇ化された成長ホルモンアンタゴニスト
CA3141128A1 (en) Therapeutic pegylated growth hormone antagonists
Nakamura et al. C-terminal cysteine PEGylation of adalimumab Fab with an engineered interchain SS bond
US20100249029A1 (en) Peptides with high affinity for the prolactin receptor
US20250101076A1 (en) Growth hormone receptor antagonists exhibiting increased receptor binding properties and increased serum half-life
KR102722602B1 (ko) 페길화된 IgE-의존적 히스타민 방출인자(HRF) 결합 펩타이드 및 이의 용도
CN114763369A (zh) 脂肪肽链及Fab-脂肪链偶联物
CN105017408B (zh) 聚乙二醇化血小板生成素模拟肽同源四聚体及其用途
EP4661892A1 (en) Tnf-alpha binding agents and methods of using the same
CN105367629B (zh) 一种促红细胞生成素模拟肽以及其制备方法和用途
HK40090811A (en) Modified l-asparaginase
HK1244016B (zh) FC融合高亲和力IGE受体α链

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210526

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250618

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250625

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250721

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250721

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260121